The Lymphatic System

The Lymphatic System
  • Excerpt

In 1987, at the Centre Huguenin in the Paris suburb of Saint-Cloud, doctor Pecking and colleagues injected the harmless radioactive “tracer” named Technetium-99m (99mTc ) into the subcutaneous space between the first toes of the feet of 40 healthy males who voluntarily participated in a study aimed at measuring the effect of Masquelier’s OPCs (Endotélon) on lymphatic motion.

[…..]

The study was a placebo controlled double-blind cross-over study, which means that half of the participants first took 300 mg OPCs per day and then, after the cross-over, the placebo, while the other half first took the placebo and then the OPCs. OPCs and placebo were taken for 1 week and in between the OPCs and placebo, there was a “wash-out” period of 2 weeks.

[…..]

In both groups, the differences between placebo and OPCs were significant. Tests were performed on days 0 and 8 (first week), 21 (ending of the “wash-out”and beginning of the 4th week) and 28 (ending of the 4th week). On days 8 and 28, the researchers observed that OPCs induce a significant improvement in the disappearing of the radioactivity and “clearing” at the location of the injection, as well as an improvement of the lymph’s velocity in the foot and lower leg.

[…..]

On average, the lymphatic speed, went up from 10.6 to 13.3 centimeters per minute in the 1st group and from 11.0 to 13.5 centimeters per minute in the 2nd group. Half life (disappearance) of the radioactivity went down from 81.8 minutes to 70.6 in the 1st group and from 83.2 to 68.7 in the 2nd. The “clearance” went up from 43.1 to 53.8 milliliters per minute in the 1st and from 41.3 to 55.8 milliliters per minute in the 2nd group. The placebo also influenced the response of the lymphatic system, but only to a minor degree. In their publication, the French researchers concluded that “oligomeric proanthocyanidins are statistically more effective to stimulate the lymphatic system in healthy people than a placebo.”

(Oligomères procyanidoliques (Endotelon®) et système lymphatique. A. Pecking, B. Picandet, K. Hacene, F. Lokiec, P. Guerin; ARTERES ET VEINES, Vol. 6, No 6, 1987.)